Skip to content

Preoperative Intraarticular Injection of Methylprednisolone in Patients Scheduled for Total Knee-arthroplasty

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02253966
Enrollment
48
Registered
2014-10-01
Start date
2014-10-31
Completion date
2016-03-31
Last updated
2016-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperalgesia, Knee Joint Osteoarthrosis, Severe Movement Related Pain

Brief summary

Despite improvements in analgesic treatment following total knee arthroplasty (TKA) for osteoarthrosis, a substantial part of patients still have severe acute pain after surgery. It has been suggested that preoperative degree of intraarticular inflammation is associated to postoperative degree of pain and level of function. Furthermore it is known, that patients with preoperative inflammation have hyperalgesia and severe movement related pain. The aim of this study is to investigate the effect of a preoperative intraarticular injection of Methylprednisoloneacetate in reducing acute postoperative pain after total knee arthroplasty in patients with signs of severe pre-operative inflammation and pain.

Interventions

DRUGLidocaine
OTHERsodium chloride

Sponsors

Lundbeck Foundation
CollaboratorOTHER
Rigshospitalet, Denmark
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age 50 -80 * Osteoarthrosis * Scheduled for primary unilateral TKA * Preoperative pain report with NRS \> 5 upon walking * Signs of sensitisation in knee

Exclusion criteria

* Allergies to methylprednisoloneacetate, lidocaine or standard analgesic treatment * Deficient written or spoken danish * Impairment from psychological or neurological disease * Local og systemic infection * Immunodeficiency * Treatment with corticosteroid within 30 days of inclusion * Insulin treated diabetes mellitus * Anticoagulant therapy * ASA (American Society of Anaesthesia) class \> 3 * General anaesthesia * Alchohol use \> 21 units / week * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Pain24 hours postoperativelyPain intensity on a numeric rang scale (NRS) from 0 to 10 upon ambulation 24 hours following surgery

Secondary

MeasureTime frameDescription
Pain48 hours postoperativelyPain intensity on a NRS from 0 to 10 upon ambulation 48 hours following
SensitisationOn day 0 and day 2Quantitative sensory testing (temporal summation / pressure algometry) on the day of surgery and on the second postoperative day.
InflammationOn day 0 and day 2Measurement of C-reactive protein in blood sample on the day of surgery and on the second postoperative day.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026